Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study

被引:4
|
作者
Cao, Guang [1 ]
Wang, Xiaodong [2 ]
Chen, Hui [1 ]
Gao, Song [1 ]
Guo, Jianhai [1 ]
Liu, Peng [1 ]
Xu, Haifeng [1 ]
Xu, Liang [2 ]
Zhu, Xu [1 ]
Yang, Renjie [2 ]
机构
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ, Dept Intervent Therapy, Beijing 100142, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Intervent Therapy, Natl Canc Ctr,Canc Hosp, Beijing 100021, Peoples R China
基金
中国国家自然科学基金;
关键词
Colorectal cancer; Hepatic arterial infusion; Liver metastasis; Regorafenib; Survival; UNRESECTABLE LIVER METASTASES; SYSTEMIC CHEMOTHERAPY; HEPATOCELLULAR-CARCINOMA; DOUBLE-BLIND; PHASE-II; OXALIPLATIN; RESECTION; 5-FLUOROURACIL; RESECTABILITY; CONVERSION;
D O I
10.1186/s12876-022-02344-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Hepatic arterial infusion chemotherapy delivers the drug directly to the liver. We aim to explore the benefits and tolerability of Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal liver metastasis refractory to standard systemic chemotherapy. Methods This study analyzed 47 patients treated with hepatic arterial infusion chemotherapy plus regorafenib after standard systemic oxaliplatin and/or irinotecan in combination with bevacizumab or cetuximab between Jan 2017 and Jun 2020. Regorafenib was given for only 3 weeks in a 4-week cycle. Results Among 47 patients, 32 (68%) were males. The median age was 61 (29-75). With a median follow-up of 22.2 months (3.7-50.7 months). Before Hepatic arterial infusion chemotherapy administration in combination with regorafenib, 34 (72.3%) patients previously received >= 2 prior lines of systemic therapy and 37 (78.7%)patients previously received targeted biological treatment (anti-VEGF or anti-EGFR, or both). The initial doses of regorafenib were 40 mg/d (n = 1, 2.13%), 80 mg/d (n = 11, 23.43%), 120 mg/d (n = 2, 4.26%), and 160 mg/d (n = 23, 48.94%), while for 24.6% (n = 14) dose was unknown. Median Overall Survival was 22.2 months. Median Progression-Free Survival was 10.8 (95% CI: 9.0-13.7) months. Common Adverse Events were hand-foot skin reaction (12.77%), fatigue (6.38%), vomiting (6.38%), and decreased appetite (6.38%). Only 2 patients discontinued regorafenib due to Adverse Events. Conclusions Regorafenib combined with Hepatic arterial infusion was effective and tolerable in patients with liver predominant metastasis of colorectal cancer. Hence, this therapy can be considered as an alternative for second- or subsequent lines of therapy in patients refractory to standard systemic chemotherapy.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study
    Guang Cao
    Xiaodong Wang
    Hui Chen
    Song Gao
    Jianhai Guo
    Peng Liu
    Haifeng Xu
    Liang Xu
    Xu Zhu
    Renjie Yang
    [J]. BMC Gastroenterology, 22
  • [2] Regorafenib plus tislelizumab for patients with metastatic colorectal cancer: A real-world study
    Gao, Xiang
    Chen, Xiaoping
    Zhao, Yutian
    Mao, Yong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Hepatic arterial infusion chemotherapy combined with bevacizumab plus a PD-1 inhibitor for gallbladder cancer with hepatic oligometastasis: a real-world study
    Zhao, Wenchao
    Yao, Zhiyuan
    Li, Jingbo
    Li, Wenping
    Dou, Qi
    Zhao, Xiangfei
    Wu, Yintao
    Xia, Nianxin
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (01) : 330 - 345
  • [4] Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study
    Khouri, Cedric
    Guiu, Boris
    Cercueil, Jean Pierre
    Chauffert, Bruno
    Ladoire, Sylvain
    Ghiringhelli, Francois
    [J]. ANTI-CANCER DRUGS, 2010, 21 (06) : 656 - 661
  • [5] Regorafenib Plus for third-line treatment in metastatic colorectal cancer: A real-world study
    Yisilamu, Patiguli
    Yao, Jiannan
    Ge, Yang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Real-world effectiveness of regorafenib in the treatment of patients with metastatic colorectal cancer: A retrospective, observational study
    Wang, Hailing
    Liu, Weiling
    Zhao, Yan
    Hu, Hongtao
    Zhang, Bin
    Yang, Shujun
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 (05) : E291 - E299
  • [7] A retrospective study of local hepatic artery infusion chemotherapy combined with regorafenib in the treatment of advanced colorectal cancer with predominant liver metastases.
    Cao, Guang
    Zhu, Xu
    Yang, Renjie
    Chen, Hui
    Wang, Xiaodong
    Liang, Xu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study
    Lim, Annie
    Le Sourd, Samuel
    Senellart, Helene
    Luet, Dominique
    Douane, Frederic
    Perret, Christophe
    Bouvier, Antoine
    Metairie, Sylvie
    Cauchin, Estelle
    Rougier, Philippe
    Matysiak-Budnik, Tamara
    Touchefeu, Yann
    [J]. CLINICAL COLORECTAL CANCER, 2017, 16 (04) : 308 - 315
  • [9] Postoperative prophylactic hepatic arterial infusion chemotherapy for stage III colorectal cancer: a retrospective study
    Wang, Yao
    Sun, Xin Rong
    Feng, Wen Ming
    Bao, Ying
    Zheng, Yin Yuan
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 5897 - 5902
  • [10] Hepatic arterial infusion chemotherapy for unresectable liver metastases of colorectal cancer: a multicenter retrospective study
    Lim, A.
    Le Sourd, S.
    Senellart, H.
    Luet, D.
    Douane, F.
    Perret, C.
    Bouvier, A.
    Metairie, S.
    Cauchin, E.
    Philippe, Rougier
    Tamara, Matysiak-Budnik
    Touchefeu, Y.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : 84 - 85